We demonstrate that the role of cyclooxygenase enzymes in arachidonic acid metabolism is altered in the nasal mucosa of aspirin-intolerant asthmatic patients. This suggests that abnormalities in cyclooxygenase enzymes are present in all the nasal mucosa of these patients. Our results provide further support to the consensus term of rhinosinusitis. 
INTRODUCTION
Aspirin-induced asthma (AIA) is a syndrome characterized by the association of asthma, chronic rhinosinusitis with nasal polyps (NP), and episodes of bronchospasm precipitated by non-steroidal anti-inflammatory drugs (NSAIDs). 1 Although the mechanism responsible for AIA has not been completely elucidated, anomalies in the regulation of arachidonic acid (AA) metabolism seem to be involved in the adverse response to NSAIDs in these patients. 1, 2 Upon stimulation, activated phospholipase A 2 releases AA from membrane phospholipids. AA is then converted by enzymatic and non-enzymatic pathways into a large number of eicosanoids. The major enzymatic routes include the lipoxygenase (LO) pathway, which is responsible for the formation of leukotrienes, 15-HETE, and lipoxins; the cyclooxygenase (COX) pathway, involved in the formation of prostaglandins (PG), thromboxanes and prostacyclin; and the cytochrome P450 pathway, responsible for the formation of 20-HETE and other metabolites. 3, 4 In the human lung, the 5-LO pathway is responsible for the synthesis of cysteinylleukotrienes (CysLTs). Various studies have reported that this pathway is up-regulated in the upper and lower airways of AIA patients. The expression of the enzyme LTC 4 synthase, which is involved in the synthesis of LTC 4 , is much higher in the airways of AIA patients than in those of aspirin-tolerant asthma patients and healthy controls. 5, 6 The increased activity of the 5-LO pathway results in overproduction of CysLTs in AIA, which is further increased when patients are exposed to NSAIDs. 7, 8 This over-expression of CysLT is a finding reported by almost all the authors who have studied the mechanism of AIA. However, the presence of anomalies in the regulation of the COX metabolism has been reported in only some of these studies, and their role in Various anomalies have been reported in the COX pathway of AIA. 1,2 Low production of PGE 2 associated with down-regulated expression of COX enzymes has been reported in NP tissue and in both fibroblasts and epithelial cells from the NP of AIA patients, [9] [10] [11] [12] [13] [14] [15] suggesting that abnormalities in AA metabolism could play a role in AIA etiology.
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However, there are no reports to date of such alterations in the NM of AIA patients. In contrast to the results obtained in NP, studies using bronchial biopsies and cultured bronchial fibroblasts from AIA and aspirin-tolerant asthma have not been able to find any differences in the expression of COX-1 and COX-2 when compared to healthy controls. 5, 16 There are no clear explanations for the reported discrepancies between the results obtained in the upper and lower airways. These discrepancies might be due, at least in part, to the fact that the regulation of COX enzymes has been extensively studied by comparing NP with NM from control subjects [10] [11] [12] [13] [14] but has yet to be studied by comparing NM from AIA patients with NM from control subjects. In other words, since inflammatory polyps are structures found in the upper airways but never seen in the lower airways, it is reasonable to ask whether the anomalies reported in the regulation of COX-1 and COX-2 expression in the upper airways are specific to NP and therefore not representative of either the NM surrounding the NP structure or the bronchial mucosa.
The objective of this study was to compare the COX pathway in the NM of AIA patients with the NM of control subjects. With this aim in mind, we studied and compared PGE 2 production and COX-1 and 2 expression in fibroblasts derived from the NM of both AIA and control subjects.
METHODS

Study population
We obtained NM specimens from 5 non-asthmatic subjects with either septal deviation or turbinate hypertrophy who had undergone nasal corrective surgery (control-NM). All the control subjects had taken aspirin or NSAIDs at clinical dosage without any untoward reactions (asthma and/or rhinitis, urticaria, angioedema or anaphylaxis). NM specimens were also collected from 5 asthmatic patients with chronic rhinosinusitis and aspirin intolerance (AIA-NM) who had undergone endoscopic sinus surgery. The clinical and demographic characteristics of the subjects are shown in Table 1 . The diagnosis of aspirin intolerance was confirmed by lysine-aspirin nasal challenge, as previously described. 17 None of the control subjects had had any oral or intranasal corticosteroid treatment for at least one month before surgery. None of the patients had any upper airway infection in the 2 weeks before surgery. All patients gave informed consent to participate in the study, which was approved by the Scientific and Ethics Committee of our Institution.
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Tissue handling and cell culture NM tissue was cut into 3 x 3 mm fragments and placed in six-well plates (NUNC, Wiesbaden, Germany) containing Dulbecco's modified Eagle's media (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 µg/ml streptomycin (Invitrogen, Carlsbad, California, USA) and 2 µg/ml amphotericin B (Sigma, St Louis, MO, USA). Cultures were placed in a 5% CO 2 humidified incubator at 37ºC. Once the fibroblasts had grown, tissue fragments were removed and the first passage was performed by adding 0.05% trypsin/0.02% ethylenediaminetetraacetic acid 
Immunofluorescence
This technique was performed as previously reported [14] . The primary antibodies were against alpha-smooth muscle actin (M0851, DAKO, Glostrup, Denmark) at dilution 1:500, vimentin at 1:100 (V5255, Sigma, Saint Louis, Missouri, USA), pan-cytokeratin 
PGE 2 and COX-2 ELISA
Concentrations of PGE 2 in supernatants were measured using enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI, USA). The assay range was 7.81-1000 pg/ml.
COX-2 protein concentrations were measured using an enzyme-linked immunosorbent sandwich assay (Zymed Laboratories, San Francisco, CA, USA). The assay range was Accepted Article
RESULTS
Culture characterization
All the cells in culture had fibroblast phenotype since 100% of cells were positive to
vimentin. There was a total absence of epithelial cells in the fibroblast cultures since no cytokeratin-positive cells were found. Smears of nasal mucosa epithelial cells were used as a positive control (Figure 1 ). No significant differences were observed in the myofibroblast percentage in fibroblast cultures (control-NM=1.6%, 1.3-3.3; AIA-NM=3.5%, 2.0-3.6, N=5).
Prostaglandin E 2 production
There were no significant differences in the production of PGE 2 at baseline in cultured fibroblasts derived from either control-NM or AIA-NM. Compared to SFM-treated cells, IL-1β significantly increased PGE 2 production at 24 hours in control-NM, but had no effect on PGE 2 secretion in fibroblasts derived from AIA-NM (Figure 2 ).
COX expression
COX-1 basal expression was not different between control-NM and AIA-NM. 
DISCUSSION
The main findings of our study were: (1) IL-1β markedly stimulated the production of PGE 2 in control-NM fibroblasts but had a non-significant effect on fibroblasts obtained from AIA-NM; (2) IL-1β stimulation increased COX-1 protein expression in fibroblasts isolated from control-NM, but not in fibroblasts obtained from AIA-NM; and (3) there was a marked increase in COX-2 protein expression following IL-1β exposure in control-NM fibroblasts, but almost no effect on fibroblasts derived from AIA-NM. This is the first study to demonstrate anomalies in the COX pathway of AA metabolism in nasal mucosa from AIA patients. Previous studies have reported decreased production of PGE 2 in nasal polyps -an anomaly that is even more marked in the nasal Accepted Article polyps of patients with AIA. 10,11, 16 In line with this finding, various studies have reported a lack of up-regulation of COX-2 in nasal polyps from both aspirin-tolerant asthma and AIA. [11] [12] [13] [14] [15] 18 For reasons that remain unclear, other studies have been unable to find any differences in the expression of COX-2 between nasal polyps and control nasal mucosa. 6, 19 As most of the studies that did not find any differences in the expression of COX-2 in AIA were performed with immunohistochemistry techniques, we used three different methods of analysis (ELISA, Western blot and immunofluorescence) to assess the level of COX-2 expression.
In our study, the three methods presented similar outcomes and confirmed that COX-2 protein is not detected in non-stimulated fibroblasts and almost fails to be up-regulated by inflammatory stimuli in the nasal mucosa of AIA. These results are in keeping with other studies showing undetectable COX-2 protein in unstimulated nasal mucosa and polyp fibroblasts. 14 In contrast, increased expression of COX-2 has been reported in nasal polyps from cystic fibrosis patients, as expected in inflammatory diseases. 20, 21 This observation adds further support to the notion that, for reasons that are still unknown, COX-2 is abnormally regulated in the nasal mucosa of patients with AIA.
Previous studies suggest that an alteration in the regulation of COX-1 may also coexist with anomalies in the regulation of COX-2 in the nasal polyps of patients with and without associated AIA. 14, 18 In this study we report that these anomalies are also present in fibroblasts derived from the nasal mucosa of AIA patients. Although it is generally accepted that COX-1 plays a limited role in inflammatory responses, mild modifications can occur in the expression of the enzyme in cells and tissues when they are stimulated by pro-inflammatory cytokines or injury. 22 The 10, 24, 25 Moreover, when the COX-2 and PGE 2 concentrations obtained by ELISA in cultures treated with IL-1β were compared, the values obtained in the NM of AIA were similar to those previously reported in NP of AIA patients 14 , indicating that these alterations are present to a similar degree in all the nasal mucosa of AIA patients.
In contrast, our study reported down-regulation of arachidonic acid metabolism in fibroblasts of nasal mucosa from AIA patients. In keeping with our findings, several studies have already reported that the COX pathways are also abnormally regulated in nasal 9 and bronchial 26 epithelial cells from aspirin-sensitive asthmatics.
The mechanisms responsible for the reported alterations in the regulation of COX-2 found in our study remain to be clarified. It is well known that inflammatory stimuli induce cellular responses through the activation of mitogen-activated protein kinases (MAPKs), and that COX-2 gene expression is also regulated by the action of Accepted Article transcription factors such as NF-κB and C/EBP, among others. The role of these proteins has recently been studied in AIA-NP fibroblasts and showed no differences in MAPK phosphorylation and transcription factor nuclear translocation, compared to control nasal mucosa cells. 27 These findings suggest that the mechanisms involved in COX down-regulation should be related to other mechanisms, such as transcription factor bindability to gene promoter, the activity of histone acetyltransferases and deacetylases, and mRNA stability.
Furthermore, the absence of any differences in the myofibroblast percentage in cultures suggests that changes in cell phenotype do not play a role in the COX pathway abnormalities found in our study. Accepted Article Accepted Article
